Aton: Subsidiary Inoviem Launches Two Preclinical Programs with Biopharma Partners
Aton Group, specializing in life sciences and medical technologies, reports on the operational progress of its subsidiary Inoviem Scientific, which is engaged in translational pharmacology. This update details the deployment of its integrated platform with biopharmaceutical partners.
Innovative Integrated Platform Developed by Inoviem Scientific
Inoviem Scientific has developed an integrated platform that combines proprietary technologies for sampling and analyzing biological samples with services for molecular characterization assisted by artificial intelligence. This platform supports its partners throughout the drug development cycle, from basic research to medical decision support in hospitals, through diagnostic solutions and therapeutic guidance. The model positions the patient sample as the common thread at each stage, offering a departure from conventional pharmaceutical development models.
Pioneering Preclinical Programs in Partnership with Biopharmaceutical Entities
Free · Every morning
Technical market signals, before the opening bell.
Bullish and bearish momentum, analyst changes, stocks to watch — automatically computed from Euronext data.
✓ Before 9 AM every morning✓ Euronext data✓ AI-powered analysis
You're in — subscription confirmed!
Your first edition is on its way. Check your spam folder and add us to your contacts.
An error occurred.
Indicative data. No investment advice. Unsubscribe at any time.
Gratuit · chaque matin
Ne ratez plus rien sur vos actions
La tendance derrière les cours. L'essentiel des valeurs Euronext en quelques minutes.
📈les valeurs en mouvement, sur la durée
🎯les objectifs d'analystes qui évoluent
📰les actualités qui font bouger les cours
tendance · 6 séances
✓ C'est fait, vous êtes inscrit !
Votre première édition arrive bientôt. Pensez à vérifier vos spams.
Une erreur est survenue.
CAC 40 · SBF 120 · données indicatives · aucun conseil en investissement · désinscription à tout moment.
Two pioneering preclinical programs are conducted in partnership with biopharmaceutical players. Thanks to its proprietary technologies, Inoviem Scientific performs functional analysis of new drug candidates directly on patient samples, ahead of clinical trials. This approach allows its partners to access data generated from real patients within reduced timelines, while preserving the integrity and spatial anatomy of the samples. Concurrently, Inoviem Scientific continues to optimize its operational and analytical capabilities to meet the sustained demand for more predictive and physiologically relevant preclinical models.
Related
SectorIndustrie Pharmaceutique et Biotechnologie›Biotechnologie
Context
Period
Period: 2025
Key reported figures
Revenue: 0.7M€
EBITDA: -0,1M€
Net income: -1,0M€
3.1M€
Guidance from the release
En 2025, nous avons tenu nos engagements : structure de coûts assainie, filiales en ordre de marche, premiers jalons commerciaux posés.
Le Groupe Aton a réalisé une amélioration relative de la performance opérationnelle.
Risks mentioned
Environnement de financement toujours sélectif pour les sociétés de biotechnologies.
Risque lié à la montée en volumes de production d'anticorps à récepteurs Fc humain.
Opportunities identified
Signature de nouveaux partenariats industriels stratégiques.
Obtention d'un financement de 500 K€ de Bpifrance.
The information presented in this article is provided for informational purposes only and does not constitute an investment recommendation, an incentive to buy or sell a financial asset, or investment advice. Readers are invited to conduct their own research before making any decision.
Investments in the stock market involve risks, including the risk of capital loss. Past performance of an asset or market is no guarantee of future results. Any investment decision should be made taking into account your personal financial situation, objectives and risk tolerance.
